Prognostic significance of serum copper in patients with cutaneous T cell lymphoma

An above normal serum copper level in a subset of patients with early mycosis fungoides lymphoma correlated with a worse prognosis compared to patients with normal copper levels. The reason for this association is unknown. We hypothesize that inflammatory cytokines such as interleukin-6 secreted by inflammatory cells in skin lesions may play a role in disease progression.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Conclusions Epidemiological studies have repeatedly helped identify definitive triggers for several diseases. As highlighted in this perspective report, previous studies strongly argue for the interplay between intrinsic factors and putative preventable extrinsic triggers/promoters for CTCL. Given the evidence of geographical regional clustering of CTCL patients, CTCL occurrence in unrelated family members and recent evidence implicating S. aureus in the pathogenesis/progression of CTCL, more research is needed to decipher the precise mechanism by which specific environmental exposures may be driving the pathogenesis of t...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions The major challenges in the development of adoptive cell therapy for T cell tumors, as mentioned above, remain fratricide, T cell aplasia and the potential for leukemic transduction or poor T cell function if used in the autologous setting. Approaches to overcome fratricide include the genetic modification and deletion of the T cell antigen in the case of long-term CAR-T cell persistence or regulated CAR-T expression. To ensure restoration of T cell immunity, transient CAR expression can be achieved incorporation of a CAR suicide gene, transient CAR expression using mRNA electroporation, or short-lived NK cell...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionThe reason for the association between the high serum copper levels and adverse prognosis is unknown. We hypothesized that interleukin-6 is secreted primarily by non-neoplastic cells at MF skin sites, leading to release of copper by the liver. Local production of interleukin-6 at the lesion sites might conceivably also promote neoplastic cell progression by stimulation of the STAT3 pathway. Further studies on the relationship between activated tumor-associated macrophages, serum copper levels, interleukin-6, or C-reactive protein and prognosis might be informative.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThe reason for the association between high serum copper and adverse prognosis is unknown. We hypothesize that IL-6 is secreted primarily by non-neoplastic cells at MF skin sites, leading to release of copper by the liver. Local production of IL-6 at lesion sites conceivably might also promote neoplastic cell progression via stimulation of the STAT3 pathway. Further studies on the relationship between activated tumor-associated macrophages, serum copper, IL-6 or C-reactive protein and prognosis might be informative.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Greater than normal serum copper levels in a subset of patients with early mycosis fungoides lymphoma correlated with a worse prognosis compared with that of patients with normal copper levels. The reason for this association is unknown. We hypothesized that inflammatory cytokines such as interleukin-6 secreted by inflammatory cells in skin lesions might play a role in disease progression.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Primary cutaneous lymphomas are a heterogeneous group of lymphoid malignancies and are the second most common group of extranodal non-Hodgkin lymphoma (NHL) following gastrointestinal lymphomas.1 NHL involving the female genitalia is unusual, posing diagnostic and therapeutic challenges.2-4 Rare cases of vulvar NHL presenting as a vulvar mass were mostly diagnosed as diffuse large B-cell lymphoma and had an aggressive course.3,5 Cases of cutaneous T-cell lymphoma (CTCL) involving the vulva have been rarely reported.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Abstract Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected. Overall lymphoma incidence rates have declined in recent...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: CA Cancer J Clin Source Type: research
Publication date: Available online 29 August 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Mudit Chowdhary, Arpit M. Chhabra, Shivam Kharod, Gaurav Marwaha Mycosis fungoides (MF) is the most prevalent subtype of cutaneous T-cell lymphoma, which is characterized by the proliferation of CD4+ T-cells. While often an indolent disease, most patients eventually develop progression from isolated patches to tumors and finally nodal or visceral involvement. Treatment choice is largely based on disease burden, though prognostic factors such as disease stage, patient age, and extra-cutaneous involvement must be taken...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Romidepsin is active in subtypes of CTCL with less favorable outcomes, such as tumor-stage and folliculotropic mycosis fungoides. Teaser Patients with cutaneous T-cell lymphoma (CTCL) who have cutaneous tumors or folliculotropic disease involvement typically have poor prognoses. Analysis of the pivotal phase 2 trial of romidepsin in relapsed/refractory CTCL showed that single-agent romidepsin induced clinical response or stable disease in the majority of patients with cutaneous tumors and/or folliculotropic disease involvement, supporting its use in these patient populations.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion We found that only a few factors can predict OS and DSS for patients with advanced MF/SS. Also, nonchemotherapy options should be preferred for front-line therapy to improve survival, outcomes, and side effects, including immunosuppression. Micro-Abstract Prognostic factors would be helpful to select patients with advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) for nonaggressive versus aggressive therapy. In 168 patients with advanced-stage MF/SS, skin stage, nodal involvement, age > 65 years, high lactate dehydrogenase, and histologic large cell transformation were associated with wors...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Copper | Cutaneous T cell lymphoma | Hematology | Leukemia | Lymphoma | Mycosis Fungoides | Myeloma | Skin | T-cell Lymphoma